메뉴 건너뛰기




Volumn 69, Issue 1, 2020, Pages 74-82

Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis

Author keywords

diarrhoea; effectiveness; stool consistency; treatment response

Indexed keywords

ALOSETRON; ELUXADOLINE; RAMOSETRON; RIFAXIMIN; GASTROINTESTINAL AGENT;

EID: 85064522070     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2018-318160     Document Type: Article
Times cited : (130)

References (64)
  • 1
    • 84862651150 scopus 로고    scopus 로고
    • Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis
    • L ovell RM, Ford AC . Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21.
    • (2012) Clin Gastroenterol Hepatol , vol.10 , pp. 712-721
    • Ovell, R.M.L.1    Ford, A.C.2
  • 3
    • 60449087280 scopus 로고    scopus 로고
    • Burden of digestive diseases in the United States part II: Lower gastrointestinal diseases
    • E verhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 2009;136:741-54.
    • (2009) Gastroenterology , vol.136 , pp. 741-754
    • Verhart, J.E.E.1    Ruhl, C.E.2
  • 4
    • 0033866061 scopus 로고    scopus 로고
    • The impact of irritable bowel syndrome on health-related quality of life
    • G ralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654-60.
    • (2000) Gastroenterology , vol.119 , pp. 654-660
    • Ralnek, I.M.G.1    Hays, R.D.2    Kilbourne, A.3
  • 5
    • 84937013009 scopus 로고    scopus 로고
    • Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation
    • Singh P, Staller K, Barshop K, et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol 2015;21:8103-9.
    • (2015) World J Gastroenterol , vol.21 , pp. 8103-8109
    • Singh, P.1    Staller, K.2    Barshop, K.3
  • 6
    • 84926421572 scopus 로고    scopus 로고
    • Faecal incontinence\-The hidden scourge of irritable bowel syndrome: A cross-sectional study
    • A tarodi S, Rafieian S, Whorwell PJ. Faecal incontinence\-The hidden scourge of irritable bowel syndrome: a cross-sectional study. BMJ Open Gastroenterol 2014;1:e000002.
    • (2014) BMJ Open Gastroenterol , vol.1 , pp. e000002
    • Tarodi, S.A.1    Rafieian, S.2    Whorwell, P.J.3
  • 7
    • 85012930438 scopus 로고    scopus 로고
    • Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea
    • Buono JL, Carson RT , Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes 2017;15:35.
    • (2017) Health Qual Life Outcomes , vol.15 , pp. 35
    • Buono, J.L.1    Carson, R.T.2    Flores, N.M.3
  • 8
    • 85017653669 scopus 로고    scopus 로고
    • Eluxadoline efficacy in ibs-d patients who report prior loperamide use
    • L acy BE, Chey WD, Cash BD, et al. Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. Am J Gastroenterol 2017;112:924-32.
    • (2017) Am J Gastroenterol , vol.112 , pp. 924-932
    • Acy, B.E.L.1    Chey, W.D.2    Cash, B.D.3
  • 9
    • 85049076072 scopus 로고    scopus 로고
    • Acg task force on management of irritable bowel syndrome
    • American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
    • Ford AC , Moayyedi P, Chey WD, et al. ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol 2018;113(Suppl 2):1-18.
    • (2018) Am J Gastroenterol , vol.113 , pp. 1-18
    • Ford, A.C.1    Moayyedi, P.2    Chey, W.D.3
  • 10
    • 85053356383 scopus 로고    scopus 로고
    • Effect of antidepressants and psychological therapies in irritable bowel syndrome: An updated systematic review and meta-analysis
    • Ford AC , Lacy BE, Harris LA, et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol 2019;114:21-39.
    • (2019) Am J Gastroenterol , vol.114 , pp. 21-39
    • Ford, A.C.1    Lacy, B.E.2    Harris, L.A.3
  • 11
    • 57749192461 scopus 로고    scopus 로고
    • Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis
    • Ford AC , Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008;337:a2313-92.
    • (2008) BMJ , vol.337 , pp. a2313-a2392
    • Ford, A.C.1    Talley, N.J.2    Spiegel, B.M.3
  • 12
    • 0033625752 scopus 로고    scopus 로고
    • Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers
    • Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000;14:775-82.
    • (2000) Aliment Pharmacol Ther , vol.14 , pp. 775-782
    • Houghton, L.A.1    Foster, J.M.2    Whorwell, P.J.3
  • 13
    • 84927797008 scopus 로고    scopus 로고
    • The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)
    • Min YW, Rhee PL. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol 2015;8:136-42.
    • (2015) Therap Adv Gastroenterol , vol.8 , pp. 136-142
    • Min, Y.W.1    Rhee, P.L.2
  • 14
    • 0031658491 scopus 로고    scopus 로고
    • Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
    • Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998;12:849-55.
    • (1998) Aliment Pharmacol Ther , vol.12 , pp. 849-855
    • Delvaux, M.1    Louvel, D.2    Mamet, J.P.3
  • 15
    • 84961197854 scopus 로고    scopus 로고
    • Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome
    • Kane JS, Ford AC . Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2016;10:431-42.
    • (2016) Expert Rev Gastroenterol Hepatol , vol.10 , pp. 431-442
    • Kane, J.S.1    Ford, A.C.2
  • 16
    • 85030873237 scopus 로고    scopus 로고
    • Eluxadoline in irritable bowel syndrome with diarrhea: Rationale, evidence and place in therapy
    • Barshop K, Staller K. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy. Ther Adv Chronic Dis 2017;8:153-60.
    • (2017) Ther Adv Chronic Dis , vol.8 , pp. 153-160
    • Barshop, K.1    Staller, K.2
  • 17
    • 78650864077 scopus 로고    scopus 로고
    • Rifaximin therapy for patients with irritable bowel syndrome without constipation
    • Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
    • (2011) N Engl J Med , vol.364 , pp. 22-32
    • Pimentel, M.1    Lembo, A.2    Chey, W.D.3
  • 18
    • 0034712539 scopus 로고    scopus 로고
    • Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial
    • C amilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-40.
    • (2000) Lancet , vol.355 , pp. 1035-1040
    • Amilleri, M.C.1    Northcutt, A.R.2    Kong, S.3
  • 19
    • 84975861217 scopus 로고    scopus 로고
    • Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women
    • Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. Gastroenterology 2016;150:358-66.
    • (2016) Gastroenterology , vol.150 , pp. 358-366
    • Fukudo, S.1    Kinoshita, Y.2    Okumura, T.3
  • 20
    • 84957818149 scopus 로고    scopus 로고
    • Eluxadoline for irritable bowel syndrome with diarrhea
    • L embo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med 2016;374:242-53.
    • (2016) N Engl J Med , vol.374 , pp. 242-253
    • Embo, A.J.L.1    Lacy, B.E.2    Zuckerman, M.J.3
  • 21
    • 67650455908 scopus 로고    scopus 로고
    • Efficacy of 5-ht3 antagonists and 5-ht4 agonists in irritable bowel syndrome: Systematic review and meta-analysis
    • Ford AC , Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009;104:1831-43.
    • (2009) Am J Gastroenterol , vol.104 , pp. 1831-1843
    • Ford, A.C.1    Brandt, L.J.2    Young, C.3
  • 22
    • 85053338498 scopus 로고    scopus 로고
    • Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: Systematic review and network meta-analysis
    • Black CJ, Burr NE, Quigley EMM, et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology 2018;155:1753-63.
    • (2018) Gastroenterology , vol.155 , pp. 1753-1763
    • Black, C.J.1    Burr, N.E.2    Quigley, E.M.M.3
  • 23
    • 77953773581 scopus 로고    scopus 로고
    • Meta-analysis: Factors affecting placebo response rate in the irritable bowel syndrome
    • Ford AC , Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010;32:144-58.
    • (2010) Aliment Pharmacol Ther , vol.32 , pp. 144-158
    • Ford, A.C.1    Moayyedi, P.2
  • 25
    • 84932084410 scopus 로고    scopus 로고
    • The prisma extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations
    • Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84.
    • (2015) Ann Intern Med , vol.162 , pp. 777-784
    • Hutton, B.1    Salanti, G.2    Caldwell, D.M.3
  • 27
    • 85164560670 scopus 로고    scopus 로고
    • Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: Many names, many benefits, many concerns for the next generation evidence synthesis tool
    • Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3:80-97.
    • (2012) Res Synth Methods , vol.3 , pp. 80-97
    • Salanti, G.1
  • 28
    • 78650509651 scopus 로고    scopus 로고
    • Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial
    • Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
    • (2011) J Clin Epidemiol , vol.64 , pp. 163-171
    • Salanti, G.1    Ades, A.E.2    Ioannidis, J.P.3
  • 29
    • 84884879422 scopus 로고    scopus 로고
    • Graphical tools for network meta-analysis in STATA
    • C haimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8:e76654.
    • (2013) PLoS One , vol.8 , pp. e76654
    • Haimani, A.C.1    Higgins, J.P.2    Mavridis, D.3
  • 30
    • 84875625927 scopus 로고    scopus 로고
    • Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies
    • Higgins JP, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110.
    • (2012) Res Synth Methods , vol.3 , pp. 98-110
    • Higgins, J.P.1    Jackson, D.2    Barrett, J.K.3
  • 31
    • 0041876133 scopus 로고    scopus 로고
    • Measuring inconsistency in meta-analyses
    • Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
    • (2003) BMJ , vol.327 , pp. 557-560
    • Higgins, J.P.1    Thompson, S.G.2    Deeks, J.J.3
  • 32
    • 84938378742 scopus 로고    scopus 로고
    • Ranking treatments in frequentist network meta-analysis works without resampling methods
    • R ücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 2015;15:58.
    • (2015) BMC Med Res Methodol , vol.15 , pp. 58
    • Ücker, G.R.1    Schwarzer, G.2
  • 33
    • 85060660745 scopus 로고    scopus 로고
    • Quantitative synthesis-an update. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD: Agency for Healthcare Research and Quality (US)
    • Morton SC, Murad MH, O'Connor E, et al. AHRQ methods for effective health care. Quantitative synthesis-an update. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD: Agency for Healthcare Research and Quality (US), 2018.
    • (2018) AHRQ Methods for Effective Health Care
    • Morton, S.C.1    Murad, M.H.2    O'Connor, E.3
  • 34
    • 0034917335 scopus 로고    scopus 로고
    • A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
    • C amilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-40.
    • (2001) Arch Intern Med , vol.161 , pp. 1733-1740
    • Amilleri, M.C.1    Chey, W.Y.2    Mayer, E.A.3
  • 35
    • 0032848856 scopus 로고    scopus 로고
    • Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist
    • C amilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-59.
    • (1999) Aliment Pharmacol Ther , vol.13 , pp. 1149-1159
    • Amilleri, M.C.1    Mayer, E.A.2    Drossman, D.A.3
  • 36
    • 8744229903 scopus 로고    scopus 로고
    • Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome
    • C hey WD, Chey WY, Heath AT , et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004;99:2195-203.
    • (2004) Am J Gastroenterol , vol.99 , pp. 2195-2203
    • Hey, W.D.C.1    Chey, W.Y.2    Heath, A.T.3
  • 37
    • 13744263696 scopus 로고    scopus 로고
    • A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS
    • C hang L, Ameen VZ, Dukes GE, et al. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005;100:115-23.
    • (2005) Am J Gastroenterol , vol.100 , pp. 115-123
    • Hang, L.C.1    Ameen, V.Z.2    Dukes, G.E.3
  • 38
    • 0034827794 scopus 로고    scopus 로고
    • Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome
    • Lotronex Investigator Team
    • L embo T, Wright RA, Bagby B, et al. Lotronex Investigator Team. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-70.
    • (2001) Am J Gastroenterol , vol.96 , pp. 2662-2670
    • Embo, T.L.1    Wright, R.A.2    Bagby, B.3
  • 39
    • 34547626592 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant ibs
    • Krause R, Ameen V, Gordon SH, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007;102:1709-19.
    • (2007) Am J Gastroenterol , vol.102 , pp. 1709-1719
    • Krause, R.1    Ameen, V.2    Gordon, S.H.3
  • 40
    • 52149088774 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both Male and female Japanese patients with diarrhea-predominant irritable bowel syndrome
    • Matsueda K, Harasawa S, Hongo M, et al. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both Male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008;43:1202-11.
    • (2008) Scand J Gastroenterol , vol.43 , pp. 1202-1211
    • Matsueda, K.1    Harasawa, S.2    Hongo, M.3
  • 41
    • 48049093262 scopus 로고    scopus 로고
    • A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese Male and female patients with diarrhea-predominant irritable bowel syndrome
    • Matsueda K, Harasawa S, Hongo M, et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese Male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008;77:225-35.
    • (2008) Digestion , vol.77 , pp. 225-235
    • Matsueda, K.1    Harasawa, S.2    Hongo, M.3
  • 42
    • 84901199541 scopus 로고    scopus 로고
    • Effect of ramosetron on stool consistency in Male patients with irritable bowel syndrome with diarrhea
    • Fukudo S, Ida M, Akiho H, et al. Effect of ramosetron on stool consistency in Male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2014;12:953-9.
    • (2014) Clin Gastroenterol Hepatol , vol.12 , pp. 953-959
    • Fukudo, S.1    Ida, M.2    Akiho, H.3
  • 43
    • 85013339837 scopus 로고    scopus 로고
    • Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study
    • Fukudo S, Matsueda K, Haruma K, et al. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study. Neurogastroenterol Motil 2017;29:e13023.
    • (2017) Neurogastroenterol Motil , vol.29 , pp. e13023
    • Fukudo, S.1    Matsueda, K.2    Haruma, K.3
  • 44
    • 84880633982 scopus 로고    scopus 로고
    • Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study
    • Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 2013;145:329-38.
    • (2013) Gastroenterology , vol.145 , pp. 329-338
    • Dove, L.S.1    Lembo, A.2    Randall, C.W.3
  • 45
    • 84957969209 scopus 로고    scopus 로고
    • Rifaximin and eluxadoline-newly approved treatments for diarrhea-predominant irritable bowel syndrome: What is their role in clinical practice alongside alosetron?
    • C ash BD, Lacy BE, Rao T, et al. Rifaximin and eluxadoline-newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Expert Opin Pharmacother 2016;17:311-22.
    • (2016) Expert Opin Pharmacother , vol.17 , pp. 311-322
    • Ash, B.D.C.1    Lacy, B.E.2    Rao, T.3
  • 46
    • 84969416291 scopus 로고    scopus 로고
    • Evaluation of alosetron using the new FDA composite endpoint demonstrates strong treatment effect in females with severe irritable bowel syndrome with diarrhea
    • C amilleri M, Krause R, Deveze S, et al. Evaluation of alosetron using the new FDA composite endpoint demonstrates strong treatment effect in females with severe irritable bowel syndrome with diarrhea. Am J Gastroenterol 2014;109:S535.
    • (2014) Am J Gastroenterol , vol.109 , pp. S535
    • Amilleri, M.C.1    Krause, R.2    Deveze, S.3
  • 47
    • 85082729029 scopus 로고    scopus 로고
    • Efficacy and safety of eluxadoline in ibs-d patients who report inadequate symptom control with prior loperamide use: A phase 4, multicenter, multinational, randomized, placebo-controlled, double-blinded study (relief): Presidential poster award
    • Brenner D, Gutman C, Jo E. Efficacy and Safety of Eluxadoline in IBS-D Patients Who Report Inadequate Symptom Control With Prior Loperamide Use: A Phase 4, Multicenter, Multinational, Randomized, Placebo-controlled, Double-blinded Study (RELIEF): Presidential Poster Award. Am J Gastroenterol 2018;113(Supplement):S254-5.
    • (2018) Am J Gastroenterol , vol.113 , pp. S254-S255
    • Brenner, D.1    Gutman, C.2    Jo, E.3
  • 48
    • 85122939744 scopus 로고    scopus 로고
    • Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome
    • A costa A, Camilleri M, Shin A, et al. Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol 2016;7:e173.
    • (2016) Clin Transl Gastroenterol , vol.7 , pp. e173
    • Costa, A.A.1    Camilleri, M.2    Shin, A.3
  • 49
    • 84902269125 scopus 로고    scopus 로고
    • Antibiotic treatment of constipation-predominant irritable bowel syndrome
    • Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci 2014;59:1278-85.
    • (2014) Dig Dis Sci , vol.59 , pp. 1278-1285
    • Pimentel, M.1    Chang, C.2    Chua, K.S.3
  • 50
    • 84880316644 scopus 로고    scopus 로고
    • Conceptual and technical challenges in network meta-analysis
    • C ipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130-7.
    • (2013) Ann Intern Med , vol.159 , pp. 130-137
    • Ipriani, A.C.1    Higgins, J.P.2    Geddes, J.R.3
  • 51
    • 0035822324 scopus 로고    scopus 로고
    • Assessing the quality of controlled clinical trials
    • Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
    • (2001) BMJ , vol.323 , pp. 42-46
    • Juni, P.1    Altman, D.G.2    Egger, M.3
  • 52
    • 84883376111 scopus 로고    scopus 로고
    • A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program
    • T ong K, Nicandro JP, Shringarpure R, et al. A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol 2013;6:344-57.
    • (2013) Therap Adv Gastroenterol , vol.6 , pp. 344-357
    • Ong, K.T.1    Nicandro, J.P.2    Shringarpure, R.3
  • 53
    • 1942440353 scopus 로고    scopus 로고
    • Occurrence of colon ischemia in relation to irritable bowel syndrome
    • C ole JA, Cook SF, Sands BE, et al. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 2004;99:486-91.
    • (2004) Am J Gastroenterol , vol.99 , pp. 486-491
    • Ole, J.A.C.1    Cook, S.F.2    Sands, B.E.3
  • 54
    • 84907499626 scopus 로고    scopus 로고
    • A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
    • G arsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014;63:1617-25.
    • (2014) Gut , vol.63 , pp. 1617-1625
    • Arsed, K.G.1    Chernova, J.2    Hastings, M.3
  • 55
    • 85076449233 scopus 로고    scopus 로고
    • R andomized, double-blind, placebo-controlled phase 2 trial of BEKINDA (ondansetron 12 mg bimodal release tablets) for diarrhea predominant irritable bowel syndrome (IBS-D)
    • R andomized, double-blind, placebo-controlled phase 2 trial of BEKINDA (ondansetron 12 mg bimodal release tablets) for diarrhea predominant irritable bowel syndrome (IBS-D). https://clinicaltrialsgov/ct2/show/ NCT02757105?term=ondansetron&cond=Irritable+Bowel+Syndrome&rank=2.
  • 56
    • 85076448873 scopus 로고    scopus 로고
    • T reatment of irritable bowel syndrome with diarrhoea using titrated ondansetron trial (TRITON)
    • T reatment of irritable bowel syndrome with diarrhoea using titrated ondansetron trial (TRITON). https://clinicaltrialsgov/ct2/show/ NCT03555188?term=ondansetron&cond=Irritable+Bowel+Syndrome&rank=1.
  • 57
    • 0032829725 scopus 로고    scopus 로고
    • Functional bowel disorders and functional abdominal pain
    • T hompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl 2):ii43-7.
    • (1999) Gut , vol.45 , pp. ii43-ii47
    • Hompson, W.G.T.1    Longstreth, G.F.2    Drossman, D.A.3
  • 59
    • 0025601811 scopus 로고
    • Identification of sub-groups of functional gastrointestinal disorders
    • Drossman DA, Thompson WG, Talley NJ. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterology Intl 1990;3:159-72.
    • (1990) Gastroenterology Intl , vol.3 , pp. 159-172
    • Drossman, D.A.1    Thompson, W.G.2    Talley, N.J.3
  • 60
    • 84888299584 scopus 로고    scopus 로고
    • Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care
    • Ford AC , Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013;145:1262-70.
    • (2013) Gastroenterology , vol.145 , pp. 1262-1270
    • Ford, A.C.1    Bercik, P.2    Morgan, D.G.3
  • 61
    • 0032749795 scopus 로고    scopus 로고
    • Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
    • Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999;13:1419-27.
    • (1999) Aliment Pharmacol Ther , vol.13 , pp. 1419-1427
    • Jones, R.H.1    Holtmann, G.2    Rodrigo, L.3
  • 62
    • 81855185606 scopus 로고    scopus 로고
    • Efficacy of ramosetron in the treatment of Male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine
    • L ee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of Male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011;23:1098-104.
    • (2011) Neurogastroenterol Motil , vol.23 , pp. 1098-1104
    • Ee, K.J.L.1    Kim, N.Y.2    Kwon, J.K.3
  • 63
    • 85057305718 scopus 로고    scopus 로고
    • Alosetron versus traditional pharmacotherapy in clinical practice: Effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome
    • Olden KW, Chey WD, Shringarpure R, et al. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. Curr Med Res Opin 2019;35:461-72.
    • (2019) Curr Med Res Opin , vol.35 , pp. 461-472
    • Olden, K.W.1    Chey, W.D.2    Shringarpure, R.3
  • 64
    • 85049731293 scopus 로고    scopus 로고
    • Assessing the efficacy of peripherally acting μ-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: Authors reply
    • Burr NE, Ford AC . Assessing the efficacy of peripherally acting μ-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: authors reply. Gut 2019;68:1530-1.
    • (2019) Gut , vol.68 , pp. 1530-1531
    • Burr, N.E.1    Ford, A.C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.